5,6-Dichloro-1-(2-morpholin-4-ylethyl)-3-[1-[1-(pyridin-4-ylmethyl)piperidine-4-carbonyl]piperidin-4-yl]benzimidazol-2-one | 633309-86-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 英文名称: 5,6-Dichloro-1-(2-morpholin-4-ylethyl)-3-[1-[1-(pyridin-4-ylmethyl)piperidine-4-carbonyl]piperidin-4-yl]benzimidazol-2-one
• CAS: 633309-86-1
• 化学式: C₃₀H₃₈Cl₂N₆O₃
• 分子量: 601.576
• InChiKey: PKQQXFIAOVUVLO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  41
• 可旋转键数：
  7
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.57
• 拓扑面积：
  72.5
• 氢给体数：
  0
• 氢受体数：
  6

文献信息

• 1-(4-PIPERIDINYL)BENZIMIDAZOLONES AS HISTAMINE H3 ANTAGONISTS
  申请人：Schering Corporation

  公开号：EP1494671B1

  公开（公告）日：2011-10-19
• Combination of an H3 antagonist/inverse agonist and an appetite suppressant
  申请人：van Heek Margaret

  公开号：US20070142369A1

  公开（公告）日：2007-06-21

  The present invention relates to pharmaceutical compositions comprising therapeutic combinations comprising: one or more H 3 antagonists/inverse agonists; one or more appetite suppressants selected from the group consisting of CB 1 antagonists/inverse agonists, sibutramine, phentermine and topiramate; and optionally one or more HMG-CoA reductase inhibitors. The invention also relates to medicaments and kits comprising the pharmaceutical compositions of the present invention, and methods of treating obesity, obesity related disorders and diabetes using the pharmaceutical compositions of the present invention.
• US7220735B2
  申请人：——

  公开号：US7220735B2

  公开（公告）日：2007-05-22